Details
Stereochemistry | RACEMIC |
Molecular Formula | C41H42N4O6.2ClH |
Molecular Weight | 759.717 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.COC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OCCC3=CC=C(C=C3)N4CCN(CC4)C(C5=CC=CC=C5)C6=CC=CC=C6
InChI
InChIKey=MVMIPBPFTZGTBS-UHFFFAOYSA-N
InChI=1S/C41H42N4O6.2ClH/c1-28-36(40(46)50-3)38(33-15-10-16-35(27-33)45(48)49)37(29(2)42-28)41(47)51-26-21-30-17-19-34(20-18-30)43-22-24-44(25-23-43)39(31-11-6-4-7-12-31)32-13-8-5-9-14-32;;/h4-20,27,38-39,42H,21-26H2,1-3H3;2*1H
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/11116287http://en.pharmacodia.com/yaodu/html/v1/chemicals/d4667ee8a72fe0f6700a7b985f9b8a97.html | http://adisinsight.springer.com/drugs/800001931 | https://www.ncbi.nlm.nih.gov/pubmed/9306262Curator's Comment: Description was created based on several sources, including http://link.springer.com/article/10.2165/00126839-200203050-00007 and http://www.ncbi.nlm.nih.gov/pubmed/9612662
Sources: http://www.ncbi.nlm.nih.gov/pubmed/11116287http://en.pharmacodia.com/yaodu/html/v1/chemicals/d4667ee8a72fe0f6700a7b985f9b8a97.html | http://adisinsight.springer.com/drugs/800001931 | https://www.ncbi.nlm.nih.gov/pubmed/9306262
Curator's Comment: Description was created based on several sources, including http://link.springer.com/article/10.2165/00126839-200203050-00007 and http://www.ncbi.nlm.nih.gov/pubmed/9612662
Watanidipine (AE0047) had been NDA filed for the treatment of hypertension in Japan. Watanidipine (as Calbren®) was awaiting registration with Mitsubishi Pharma Corporation in Japan. However, Mitsubishi Pharma Corporation has discontinued the development of this drug. Watanidipine had also been in phase II clinical trials for the treatment of stroke and preclinical trials for atherosclerosis. However, no recent development has been reported. Watanidipine (AE0047) has being shown to be a calcium antagonist with protective effects against cerebral ischaemia and the occurrence of stroke in several animal models.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
11.4 nM [Kd] | |||
Target ID: Low-density lipoprotein (LDL) oxidation Sources: http://www.ncbi.nlm.nih.gov/pubmed/9493553 |
|||
Target ID: L-type calcium current, Cavia porcellus Sources: http://www.ncbi.nlm.nih.gov/pubmed/9612662 |
11.4 nM [Kd] | ||
Target ID: Calcium uptake Sources: http://www.ncbi.nlm.nih.gov/pubmed/9612662 |
|||
Target ID: Calcium channel |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
For essential hypertension - orally, once-daily 2-8 mg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9378237
After 1-hr treatment with Vatanidipine (10(-6) M), K(+)-induced contraction in rat aortic strip was slightly depressed
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID7021443
Created by
admin on Sat Dec 16 07:51:57 GMT 2023 , Edited by admin on Sat Dec 16 07:51:57 GMT 2023
|
PRIMARY | |||
|
446I981RBG
Created by
admin on Sat Dec 16 07:51:57 GMT 2023 , Edited by admin on Sat Dec 16 07:51:57 GMT 2023
|
PRIMARY | |||
|
133743-71-2
Created by
admin on Sat Dec 16 07:51:57 GMT 2023 , Edited by admin on Sat Dec 16 07:51:57 GMT 2023
|
PRIMARY | |||
|
154437
Created by
admin on Sat Dec 16 07:51:57 GMT 2023 , Edited by admin on Sat Dec 16 07:51:57 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD